FDA “Independent Consultant” Guidance Implements PDUFA III Provision
Executive Summary
FDA is ruling out the use of prospective clinical trial investigators as independent consultants for protocol reviews requested by sponsors, the agency indicated in a draft guidance
You may also be interested in...
FDA Biotech Consultants Should Be Vetted By Companies, BIO Says
The Biotechnology Industry Organization is asking FDA to allow sponsors to review the agency's choice of outside consultants as part of its clinical protocol evaluation program
FDA Biotech Consultants Should Be Vetted By Companies, BIO Says
The Biotechnology Industry Organization is asking FDA to allow sponsors to review the agency's choice of outside consultants as part of its clinical protocol evaluation program
PDUFA III Implementation Begins: FDA Working Groups Under Way
FDA's PDUFA III implementation program includes three working groups focusing on changes to the review process under the new user fee program